New drug trial offers hope for rare, Life-Threatening immune disorder
NCT ID NCT07339345
Summary
This study is testing an oral medication called Golidocitinib as a standalone treatment for hemophagocytic lymphohistiocytosis (HLH), a rare and severe immune system disorder. It aims to see if the drug can effectively control the disease and is safe for patients aged 14-70 who are newly diagnosed or have not responded to prior treatments. The trial is for patients who are currently not suitable for a stem cell transplant, which is a standard but intensive therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.